Printer Friendly

Troponin I in patients without chest pain.

Cardiac troponin T (cTnT) and cTn [5] are currently used as sensitive and specific laboratory markers to assess the presence of myocardial damage (1, 2). Furthermore, numerous studies have revealed the value of cTnI and cTnT as predictive markers for adverse outcomes (3-5). However, most of this research has been directed toward the applicability of these laboratory tests for patients with typical symptoms of acute coronary syndromes (ACS), specifically those presenting with unstable angina (3-5). It has been recognized that older patients or females with ACS frequently present with symptoms other than chest pain (CP; anginal equivalent symptoms), such as shortness of breath (SOB), general weakness (WK), or pain at a site other than the chest (PAIN) (6, 7). For clinicians, it is often difficult to recognize the cardiac origin of anginal equivalent symptoms because patients with diseases other than ACS often present with the same complaints. In addition, other cardiac diseases, such as heart failure, may be associated with myocardial necrosis and increased cTnI similar to ACS, leading to further confusion. In contrast to ACS, the clinical value of a positive cTnI is currently not well established for other cardiac diseases, and we are not aware of consensus documents that state how to follow up these patients. A survey completed at our hospital indicated that low-positive cTnI values are frequently not used for diagnostic or prognostic purposes when patients' complaints, clinical histories, and other diagnostic procedures do not support the diagnosis of ACS.

More recently, some research has focused on the prognostic value of cTnI and cTnT in patients with chronic renal failure (8, 9), hypovolemic shock, sepsis (10), or heart failure (11). Preliminary results of these studies have been limited, in part because of small study sizes, limited statistical analyses, or various underlying mechanisms not necessarily related to coronary artery disease. For example, with regard to increased cTnT in asymptomatic patients with end-stage renal failure, it has been shown that the kidney is unlikely to be the source of circulating cTnT (12). However, it is currently not known whether the release of cTnT in patients with renal failure is related to cardiac ischemia or to another type of mechanism.

The purpose of this study was to evaluate the utilization and prognostic value of cTnI testing in a population of patients presenting with anginal equivalent symptoms of ACS. We first investigated the frequencies of completed cTnI tests for patients with and without CP. We then compared the value of cTnI for predicting adverse outcome among patients with CP, patients with anginal equivalent symptoms, and patients with a history of congestive heart failure (CHF).

Materials and Methods


This study was conducted at the metropolitan Veterans Affairs Medical Center. Approval for the study was obtained from the local Institutional Review Board. We included all veterans who submitted specimens to the clinical laboratory for initial cTnI testing during 5 consecutive months. Patients who underwent repeated testing for cTnI were included only once in the study, using the initial test result. Patients were excluded when no cTnI results were available (rejected or lost specimens). Patients were excluded from outcome analysis when there was no documentation of follow-up visits after initial cTnI testing, as described in the section on outcome/follow-up.


Testing for cTnI was performed at a central laboratory that serves an acute-care facility and several outpatient clinics. On receipt, the heparin-plasma specimens were immediately processed and analyzed for cTnI with the AxSYM immunoanalyzer (Abbott Laboratories). The limit of detection for the AxSYM cTnI assay was determined by testing aliquots of normal pooled plasma for cTnI on 22 consecutive days. The 95th percentile limit of detection (2 SD) was 0.146 [micro]g/L (mean rate readings at 0.0 and 2.3 [micro]g/L cTnI, 11.27 and 42.77; SD, 1.02). The upper limits of the reference intervals for cTnI containing 99% of test results in middle-aged or older patients without evidence of cardiac disease have been determined previously and were 0.4 (13) or 0.6 [micro]g/L (14), respectively. The CV were ~45%, 20%, and <10% at 0.2, 0.5, and 2.0 [micro]g/L (13), respectively. Although values <0.5 [micro]g/L were reported as negative to clinicians, for the purposes of this study we recorded all results independent of this clinical cutoff.


In addition to cTnI, this prospective cohort study evaluated patients' clinical charts for complaints at the time of cTnI testing, demographic data (age, gender, and race), risk factors [body mass index (BMI), cholesterol, mean blood pressure, history of coronary artery disease, previous cerebrovascular accident, angioplasty, serum creatinine, and smoking], major diseases [e.g., diabetes, CHF, chronic obstructive pulmonary disease (COPD), and cancer] and severity of current conditions (outpatient vs inpatient). Furthermore, medical charts were evaluated for documentation of final diagnoses or explanations of the complaints that prompted cTnI testing. To avoid reviewer bias, investigators were blinded to the cTnI results during the collection of clinical data and adverse outcome data. The electronic medical charts were reviewed by four medically trained investigators for patients' symptoms at the time of cTnI testing. A single reviewer examined each patient's chart, and spot reviews were performed to assure consistency among the four reviewers. Charts containing discrepant or incomplete information underwent a repeated review by an independent investigator. Advice from a board-certified cardiologist was sought for settlement of discrepancies. The study group was then classified into six groups according to the following clinical presentations, based on the likelihood of a possible underlying cardiac disorder: (a) CP; (b) arrhythmia (ARRY); (c) SOB/WK; (d) PAIN; (e) mental status changes (MSC); and 0 patients with a history of surgery (SURG). Patients presenting with more than one of these symptoms were categorized according to the above ranking, starting with CP (e.g., a patient presenting with CP and MSC was placed in the CP group). The diagnoses of CHF as recorded in the medical charts were based mostly on clinical criteria (signs found at physical examination, echocardiogram, and chest x-ray findings).


One hundred charts underwent a second review by an independent reviewer to estimate the accuracy of chart review by the four reviewers. There was a 100% concordance between initial and repeat chart review (95% confidence interval, 96-100%) for dates of testing or death, demographics, laboratory test results, and type of outcome. The concordance rates for clinical symptoms and presence of major diseases were 98% (93-100%) and 96% (90-99%), respectively.


The clinical endpoint was chosen to be all-cause death because the cardiac contribution to death is often difficult to evaluate in patients with multiple medical conditions. Patients were followed up for 200 days from the time of their initial enrollment in the study, through review of each patient's electronic medical chart at the St. Louis Veterans Affairs Medical Center or through inquiry at the Regional Office of the Department of Veterans Affairs in St. Louis. A follow-up period of 200 days was chosen for comparability with other studies (15,16). The electronic charts were updated during the patients' scheduled visits, and information about a patient's death was documented in the database. We were unable to determine the outcome of patients who had no activities recorded at the Veterans Affairs Medical Center or at the Regional Office during a time period extending 200 days after the initial cTnI testing. These individuals were excluded from the outcome analysis of the study.


For the estimation of odds ratios, patients were divided into four groups according to their cTnI (see Table 4). The first tier consisted of patients with cTnI below the limit of detection. The second tier included patients with cTnI higher than the limit of detection but not exceeding the 99th percentile cutoff for cTnI in healthy middle-aged individuals (13). The third tier was composed of patients with cTnI between the upper limit of the 99th percentile and the former cutoff for acute myocardial infarction (2.0 [micro]g/L), which was used (17) before the introduction of new guidelines by the American College of Cardiology (18). The final tier comprised patients with cTnI at or above the former cutoff for myocardial infarction.


Characteristics of study groups were evaluated for significant differences by ANOVA or [chi square] test. The association between mortality and each of the other continuous variables was analyzed by the Student t-test. The association between mortality and each of the dichotomous variables was analyzed by the Fisher exact test. Those variables that appeared to be significant by either the Student Mest or Fisher exact test were further examined by multivariate logistic regression analysis, using the Statistical Package for the Social Sciences, Ver. 11 (SPSS Inc.). A two-tailed P value <0.05 was considered significant. Multivariate logistic regression analysis with backward deletion was performed to identify independent predictors of adverse outcome, with all-cause mortality as the dependent variable and the independent variables in the following order: BMI, creatinine, mean blood pressure, age, cerebrovascular accident, cancer, and cTnI. Troponin was entered into the model either as a continuous value or as a categorical value as defined above. Separate logistic regression models were run for the following populations: group with CP, group with SOB/WK, group with ARRY/PAIN/MSC, group with SURG, group with CHF. Standard measures of logistic regression model fit, such as the model [chi square] and Nagelkerke's [R.sup.2], were calculated (19). The limit of detection was calculated with the EP Evaluator software, Ver. 5 (David Rhoads Associates).



A total of 1184 individuals underwent testing for cTnI between July and November 2000. Patients were evaluated for their clinical symptoms at the time of presentation and were then classified according to complaints as shown in Table 1. There were 69 patients with CP who also had at least one of the other symptoms listed in Table 1. Similarly, 5 patients with ARRY, 16 patients with SOB/WK, 8 patients with PAIN, and no patients with SURG or MSC presented with more than one of the complaints as shown in Table 1. Very few patients reported irregular, slow, or fast heart beat in the absence of CP (ARRY). The second largest group consisted of patients who presented with shortness of breath, general weakness, low systemic blood pressure, or unexpected swelling of extremities (SOB/WK). Patients classified as having atypical pain (PAIN) presented with pain in the head, neck, upper or lower extremities, or abdomen, without pain in the thorax region. Symptoms of mental status changes (MSC) included loss of consciousness, nausea, confusion, numbness, dizziness, or sudden paresis. The surgery group consisted of patients who underwent surgery but otherwise did not have any of the symptoms listed in Table 1. Almost all of these surgeries involved repair of noncardiac tissue. According to chart review, cTnI testing was performed in three surgical patients for preoperative cardiac risk assessment and in five additional patients with postsurgical complications (e.g., infection or poor recovery) for exclusion of myocardial infarction. Possible reasons for cTnI testing of the remaining surgical patients may have been related to perisurgical evaluation for myocardial infarction.


The percentages of patients who were diagnosed with ACS or myocardial infarction after initial cTnI testing are listed in Table 1. For example, 9% of all patients with CP and initial cTnI [greater than or equal to] 0.1 Ag/L were subsequently diagnosed with ACS, whereas 91% of these patients received another diagnosis. The frequencies of the final diagnosis of ACS were not significantly different among patients with cTnI <0.1 [micro]g/L whether they presented with CP or with other symptoms. In contrast, the patient groups with intermediate cTnI values (0.2-1.9 [micro]g/L) differed significantly with respect to the recognition of ACS. Patients with CP, ARRY, or SURG and intermediate cTnI were most often diagnosed with ACS. Finally, a diagnosis of ACS was given to most or all patients with initial cTnI >2 [micro]g/L regardless of their complaints at the time of the initial presentation. Patients with cTnI >2 [micro]g/L and no diagnosis of ACS were judged by the treating physicians to have myocardial necrosis not related to coronary artery disease (cardiac procedures such as cardioversion, heart failure, and systemic hypoperfusion) as documented in the medical notes.


Demographics, cardiac risk factors, and information about major diseases were collected from the patients as shown in Table 2. ANOVA revealed that the six patient groups did not differ by median cTnI concentrations. However, the groups differed significantly with respect to cardiac risk factors (BMI and blood cholesterol) and a history of coronary artery disease, with patients in the CP group having the highest values for these characteristics. Likewise, the groups differed with respect to serum creatinine, age, and the frequency of patients with CHF, with the greatest values in the SOB/WK group. Other significant differences among the groups were for COPD, cancer, and proportion of inpatients with the highest values in the group undergoing surgery. Significant differences did not exist between the groups for the remaining characteristics: mean blood pressure, gender, smoking, diabetes, angioplasty, or previous cerebrovascular accident (Table 2).



There were nine patients (0.8%) for whom follow-up information was not available. They were therefore excluded from outcome analysis. Adverse outcome after cTnI testing differed significantly among patients depending on their clinical presentation (Fig. 1) at days 12, 25, 50, 100, and 200 (CP, 6%; ARRY, 21%; SOB/WK, 27%; PAIN, 13%; MSC, 13%; SURG, 30%; P <0.0001, [chi square] test). For all groups except patients undergoing surgery, the crude death rate (unadjusted death rate) showed a semilogarithmic relationship between adverse outcome and the follow-up period. For the patients in the surgery group, there was a marked increase in mortality starting at 25 days after cTnI testing. These patients were therefore analyzed separately from the other groups in subsequent multivariate analyses. For further analysis, we chose the adverse outcome at a follow-up period of 200 days.


cTnI concentrations were lower in surviving patients than in patients who died during the 200 days after laboratory testing (median, 0.1 and 0.3 [micro]g/L; 25th percentile, 0 and 0 [micro]g/L; 75th percentile, 0.4 and 0.8 [micro]g/L; range, 0-91 and 0-139 [micro]g/L, respectively). cTnI [greater than or equal to] 2.0 [micro]g/L was confirmed to be a significant predictor of adverse outcome for patients with CP (Table 3). BMI, age, and cancer were also shown to be predictors of adverse outcome in the CP group. Patients with SOB/WK and cTnI >_0.2 [micro]g/L had a higher mortality rate than similar patients with cTnI [less than or equal to] 0.1 [micro]g/L. However, cTnI did not contribute additional information for adverse outcome of patients with SOB/WK when cTnI was entered into our model as a continuous value (data not shown) rather than a categorical value. BMI, serum creatinine, blood pressure, age, and history of cancer were also identified as predictors of adverse outcome in the SOB/WK patient group (Table 3). cTnI results were not significantly associated with subsequent adverse outcome among patients with PAIN, ARRY, or MSC (Table 3). However, other variables, such as BMI and age, were predictors of death for patients with PAIN/ARRY/MSC. There was no significant association between mortality and the variables listed in Table 3 for patients who had undergone surgery (data not shown). The [chi square] and Nagelkerke's [R.sup.2] for the analyses for patients with CP, SOB, and PAIN/ARRY/MSC were 11.73, 22.72, and 6.35 and 0.25, 0.28, and 0.31, respectively.


We investigated in more detail the relationship between cTnI and subsequent adverse outcome for patients with CP or SOB/WK. To calculate the odds of adverse outcome, we used four tiers of cTnI concentration ranges as defined in the Materials and Methods. Patients presenting with CP and a cTnI in the second or third tier did not have a significantly increased mortality compared with the tier one baseline. The odds of adverse outcome were significantly higher among patients with CP when they had a cTnI within the fourth tier (Table 3). Patients presenting with SOB/WK and a cTnI in the second tier had an increased adverse outcome compared with patients with a cTnI in the tier one baseline. Patients with cTnI within the third and fourth tiers also showed a significantly higher mortality (Table 4). Thus, in contrast to the CP group, SOB/WK patients exhibited an increased mortality at cTnI values that exceeded the first tier.


We determined whether cTnI had prognostic value for patients according to diagnosis. Among the 1175 patients, there were 274 patients who had previously been diagnosed with CHF. Of these patients, 218 survived and 56 patients died within the 200-day period after initial laboratory testing. The odds of adverse outcome were significantly higher for patients with cTnI in the second, third, or fourth tier compared with patients with cTnI in the first tier (Table 4). cTnI also provided significant prognostic information when patients were classified according to diseases other than CHF. cTnI predicted the adverse outcome for patients with histories of diabetes, coronary artery disease, cerebrovascular accident, or COPD (data not shown).

More than one-third of the 405 patients with SOB/WK had documentation of increased serum creatinine (>14 mg/L) before or at the time of clinical presentation, suggesting that they may have had impaired renal function. The prognostic value of cTnI was examined in the remaining 264 patients with SOB/WK who had serum creatinine concentrations within the reference interval. Patients with cTnI in the second (odds ratio, 3.12; 95% confidence interval, 1.33-7.32; n = 66; P <0.01) or fourth tier (odds ratio, 7.02; 95% confidence interval, 1.93-25.64; n = 14; P <0.01) continued to have an increased mortality during the 200-day follow-up period compared with patients with normal renal function and cTnI in the first tier (n = 139). The difference in outcome was not significant for patients with cTnI in the third tier (odds ratio, 2.56; 95% confidence interval, 0.97-6.78; n = 45).


The diagnostic and prognostic utility of cTnI or cTnT testing has been firmly established among patients with ACS, e.g., patients who present with unstable angina or with evidence of non-ST-segment-elevation myocardial infarction (20). However, older patients with ACS frequently present with other symptoms, such as pain in areas other than the chest, SOB, weakness, or mental status changes (6, 7). Because our hospital serves a patient population with a mean age of ~65 years, we asked how often testing for cTnI is requested for patients who present with symptoms other than CP. We found that cTnI was ordered most often for patients who did not present with angina at our institution. We hypothesize that the high number of cTnI requests for patients with symptoms other than CP at our hospital is not unusual and may be similar at other hospitals that serve an older patient population (7). To our knowledge, there is currently little published information about the predictive value of cTnI for patients with anginal equivalent symptoms of ACS.

Patients are classified into three groups according to their likelihood of ACS (18). Algorithms have been developed for further evaluation and management of patients with possible or definite ACS. In contrast, there is currently no consensus as to whether to follow up patients with a low likelihood of ACS, such as patients without a recent history of CP, nondiagnostic echocardiographic findings, or cTnI below the 99th percentile of normal. We investigated how many of the patients with cTnI orders received a final diagnosis that was consistent with ACS. At our institution, only a few of the patients with symptoms other than CP or ARRY and initial cTnI <2 [micro]g/L were diagnosed with ACS at the time of their hospital visit. In contrast, most patients with anginal equivalent symptoms and higher cTnI concentrations were found to have ACS. This suggests that the laboratory test result was an important component of the diagnostic process. We believe that the rare diagnosis of ACS among patients with anginal equivalent symptoms and low-positive cTnI is not unique to this institution because many of our physicians also practice at other hospitals, including two University Medical Centers. It has been recognized that the diagnosis of ACS among patients with anginal equivalent symptoms remains a challenge for the clinician.

We next investigated the outcome for the study patients. We categorized patients without CP according to major clinical manifestations. We identified five types of manifestation or clinical circumstances, as shown in Table 1, that may have been associated with a cardiac etiology. The endpoint all-cause death was chosen because cause-specific death is often difficult to determine for patients with multiple major diseases. Follow-up information was available for >99% of study patients. It is unlikely that the exclusion of the remaining patients without available outcome information had a major effect on our observations and conclusions.

All-cause mortality differed significantly among patients according to the type of manifestation. Patients with CP had a low mortality that was similar to the mortality of patients with cardiac ischemia, as described in previous studies (4,5). The low mortality may have been attributable to the fact that these patients were most likely considered to have ACS, and therapeutic intervention has led to significant improvement of patient outcome in this patient population. On the other hand, patients with a history of recent surgery had the highest mortality rate during the follow-up period. These patients were mostly inpatients and frequently had diseases of poor prognosis, such as cancer. Patients with SOB/WK had a mortality rate that was severalfold higher than that of patients with CP. A high mortality rate has been reported previously for patients with CHF (21), similar to our patient population with SOB/WK.

We then evaluated whether testing for cTnI provided prognostic value in addition to the knowledge about demographic characteristics, cardiac risk factors, other major diseases, or severity of disease. cTnI provided additional prognostic information for most patients when they were classified according to major diseases as listed in Table 2. Additionally, cTnI at concentrations greater than the former cutoff for myocardial infarction predicted adverse outcomes for patients with CP, as reported previously (4,5). cTnI also provided significant prognostic information for patients with SOB/WK. In contrast to patients with CP, these patients had a significantly increased mortality rate at any detectable concentration of cTnI, including concentrations currently considered to be normal.

SOB/WK may be attributable to various underlying conditions, including cardiac decompensation with or without ACS. Many of the patients presenting with SOB/WK at this medical center had a history of CHF, indicating that they may have presented with deterioration of cardiac function in addition to ACS. Further analysis of patients with a history of CHF and any complaints indicated that testing for cTnI had independent prognostic value that was similar to that for patients with SOB/WK. Low circulating concentrations of cTnI detected by a highly sensitive research assay have been reported for patients with CHF (22). However, the prognostic value of cTnI or cTnT for patients with unstable heart failure is currently unclear because previously published studies have reported inconsistent results (23-27). This may have been attributable to small study sizes, lack of control for confounding factors, or variability in the performance of commercial cTnI assays. Indeed, cTnI assays are currently not standardized (28) and produce variable results, especially in the low-positive range. Preliminary data collected by our group (14) and others (22) indicated that the detection rate of cTnI in patients with heart failure is highly variable among different commercial assays. In the current study, a commercial cTnI assay was used that has previously been found to detect the low cTnI concentrations that circulate in patients with unstable heart failure (14). The performance of this assay may be different at other cutoffs and in patient populations that present with classic symptoms of ACS, such as CP (29).

There are several limitations that apply to our study. The first limitation is that patients were classified according to symptoms. For example, we did not examine whether the patients with CP had acute cardiac ischemia. This group of patients may have included individuals without coronary artery disease. Similarly, patients with SOB/WK may have been symptomatic because of underlying diseases other than cardiac decompensation (e.g., asthma, neuromuscular disease, or COPD). Testing for cTnI may have led to the identification of patients with heart failure because patients with SOB and other pulmonary diseases usually test negative for cTnI. Therefore, cTnI may have diagnostic rather than prognostic utility for patients with SOB/WK. The second limitation is that study patients were predominantly male and presented with acute symptoms. The findings from this study cannot be applied to patients with stable or asymptomatic heart failure. The third limitation is that several other factors have been found to be strong predictors of outcome in CHF, e.g., plasma norepinephrine, brain natriuretic peptide, left ventricular ejection fraction, peak [O.sub.2] consumption, or therapeutic medications (30). These factors were not assessed in our patients with SOB/WK or CHF. Therefore, it is unclear whether cTnI truly provides independent prognostic value. However, testing for cTnI is readily available in most emergency departments and may be used as a simple tool to identify patients with poor prognoses. The fourth limitation is that the current generation of commercial cTnI assays (including the first-generation assay used in this study) is imprecise at low concentrations and does not meet clinical requirements (13, 18). Therefore, it is very likely that several study patients with cTnI in the first through third tiers were incorrectly classified because of the inherent test imprecision. Random assay imprecision will lead to underestimation of the prognostic value for cTnI. Nevertheless, the large size of our study population allowed us to clearly demonstrate the potential of cTnI testing for symptomatic patients despite the technical limitations of the current assay(s). However, test results indicating detectable but very low cTnI concentrations should not be used for treatment decisions unless assays are used with improved low-end analytical sensitivity and precision.

We thank Arthur J. Labovitz, MD, Director of the Division of Cardiology, St. Louis University, and Lewis R. Chase, MD, Chief of Medical Service at the John Cochran Veterans Administration Medical Center, for review of the manuscript.


(1.) Katus HA, Looser S, Hallermayer K, Remppis A, Scheffold T, Borgya A, et al. Development and in vitro characterization of a new immunoassay of cardiac troponin T. Clin Chem 1992;38:386-93.

(2.) Adams JE III, Bodor GS, Davila-Roman VG, Delmez JA, Apple FS, Ladenson JH, et al. Cardiac troponin I a marker with high specificity for cardiac injury. Circulation 1993;88:101-6.

(3.) Heidenreich PA, Alloggiamento T, Melsop K, McDonald KM, Go AS, Hlatky MA. The prognostic value of troponin in patients with non-ST elevation acute coronary syndromes: a meta-analysis. J Am Coll Cardiol 2001;38:478-85.

(4.) Apple FS, Wu AH, Jaffe AS. European Society of Cardiology and American College of Cardiology guidelines for redefinition of myocardial infarction: how to use existing assays clinically and for clinical trials. Am Heart J 2002;144:981-6.

(5.) Christenson RH, Duh SH, Newby LK, Ohman EM, Califf RM, Granger CB, et al. Cardiac troponin T and cardiac troponin I: relative values in short-term risk stratification of patients with acute coronary syndromes. Clin Chem 1998;44:494-501.

(6.) Antman EM, Braunwald E. Acute myocardial infarction. In: Braunwald E, Zipes DP, Libby P, eds. Heart disease: a textbook of cardiovascular medicine. Philadelphia: WB Saunders Co., 2001: 1114-218.

(7.) Calle P, Jordaens L, De Buyzere M, Rubbens L, Lambrecht B, Clement DL. Age-related differences in presentation, treatment and outcome of acute myocardial infarction. Cardiology 1994;85: 111-20.

(8.) Mockel M, Schindler R, Knorr L, Muller C, Heller G, Stork TV, et al. Prognostic value of cardiac troponin T and I elevations in renal disease patients without acute coronary syndromes: a 9-month outcome analysis. Nephrol Dial Trans 1999;14:1489-95.

(9.) Wayand D, Baum H, Schatzle G, Scharf J, Neumeier D. Cardiac troponin T and I in end-stage renal failure. Clin Chem 2000;46: 1345-50.

(10.) Arlati S, Brenna S, Prencipe L, Marocchi A, Casella GP, Lanzani M, et al. Myocardial necrosis in ICU patients with acute non-cardiac disease: a prospective study. Intens Care Med 2000;26:31-7.

(11.) Jaffe AS. 2001-a biomarker odyssey. Clin Chim Acta 1999;284: 197-211.

(12.) Davis GK, Labugger R, Van Eyk JE, Apple FS. Cardiac troponin T is not detected in Western blots of diseased renal tissue. Clin Chem 2001;47:782-3.

(13.) Peetz D, Hafner G, Lackner KJ. Analytical characteristics of the AxSYM cardiac troponin I and creatine kinase MB assays. Clin Chem 2002;48:1110-1.

(14.) Lewis JS Jr, Taylor JF, Miklos AZ, Virgo KS, Creer MH, Ritter DG. Clinical significance of low-positive troponin I by AxSYM and ACS:180. Am J Clin Pathol 2001;116:396-402.

(15.) Hamm CW, Heeschen C, Goldmann B, Vahanian A, Adgey J, Miguel CM, et al. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. N Engl J Med 1999;340:1623-9.

(16.) Moeckel M, Heller G, Berg K, Klefisch FR, Danne 0, Mueller C, et al. The acute coronary syndrome diagnosis and prognostic evaluation by troponin I is influenced by the test system affinity to different troponin complexes. Clin Chim Acta 2000;293:139-55.

(17.) Apple FS, Maturen AJ, Mullins RE, Painter PC, Pessin-Minsley MS, Webster RA, et al. Multicenter clinical and analytical evaluation of the AxSYM troponin I immunoassay to assist in the diagnosis of myocardial infarction. Clin Chem 1999;45:206-12.

(18.) Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. (accessed January 2003).

(19.) Hosmer DW, Hosmer T, Le Cessie S, Lemeshow S. A comparison of goodness-of-fit tests for the logistic regression model. Stat Med 1997;15:965-80.

(20.) Yeghiazarians Y, Braunstein JB, Askari A, Stone PH. Unstable angina pectoris. N Engl J Med 2000;342:101-14.

(21.) CDC. Mortality from congestive heart failure-United States, 1980-1990. JAMA 1994;271:813-4.

(22.) Missov E, Calzolari C, Pau B. Circulating cardiac troponin I in severe congestive heart failure. Circulation 1997;96:2953-8.

(23.) Chen YN, Wei JR, Zeng U, Wu MY. Monitoring of cardiac troponin I in patients with acute heart failure. Ann Clin Biochem 1999;36:433-7.

(24.) Porela P, Helenius H, Pulkki K, Peltola O, Haenninen KP, Pettersson K, et al. Cardiac decompensation during an ischemic event weakens the predictive power of myocardial injury markers. Clin Chim Acta 2000;302:133-44.

(25.) Setsuta K, Seino Y, Takahashi N, Ogawa T, Sasaki K, Harada A, et al. Clinical significance of elevated levels of cardiac troponin T in patients with chronic heart failure. Am J Cardiol 1999;84:608-11.

(26.) La Vecchia L, Mezzena G, Ometto R, Finocchi G, Bedogni F, Soffiati G, et al. Detectable serum troponin I in patients with heart failure of nonmyocardial ischemic origin. Am J Cardiol 1997;80: 88-90.

(27.) Kollef MH, Ladenson JH, Eisenberg PR. Clinically recognized cardiac dysfunction: an independent determinant of mortality among critically ill patients: is there a role for serial measurement of cardiac troponin I? Chest 1997;111:1340-7.

(28.) Wu AHB, Feng YJ, Moore R, Apple FS, McPherson PH, Buechler KF, et al. Characterization of cardiac troponin subunit release into serum after acute myocardial infarction and comparison of assays for troponin T and I. Clin Chem 1998;44:1198-208.

(29.) Venge P, Lagerqvist B, Diderholm E, Lindahl B, Wallentin L. Clinical performance of three cardiac troponin assays in patients with unstable coronary artery disease (a FRISC II substudy). Am J Cardiol 2002;89:1035-41.

(30.) Eichhorn EJ. Prognosis determination in heart failure. Am J Med 2001;110:14S-34S.


Departments of [1] Pathology, [2] Surgery, and [3] Cardiology, Saint Louis University School of Medicine, St. Louis, MO 63104.

[4] John Cochran Veterans Affairs Medical Center, St. Louis, MO 63106.

[5] Nonstandard abbreviations: cTnI and cTnT, cardiac troponin I and troponin T, respectively; ACS, acute coronary syndrome; CP, chest pain; CHF, congestive heart failure; SOB/WK, shortness of breath or weakness; PAIN, pain at site other than chest; BMI, body mass index; COPD, chronic obstructive pulmonary disease; ARRY, arrhythmia; MSC, mental status changes; and SURG, surgery.

* Address correspondence to this author at: Pathology, Saint Louis University Hospital, 3635 Vista Ave., St. Louis, MO 63110. Fax 314-268-5104; e-mail

Received January 8, 2003; accepted September 30, 2003.

Previously published online at DOI: 10.1373/clinchem.2003.016311
Table 1. Complaints of Veterans Administration Medical Center patients
at the time of laboratory testing for cTnI and percentage of patients
with a final diagnosis of ACS according to complaints and initial cTnI.

 Patients with a clinical diagnosis of ACS, %

 cTnI [less than or cTnI 0.2-0.4
Complaints n % equal to] 0.1 [micro]g/L [micro]g/L

CP 462 39.0 9 13
ARRY 34 2.9 0 0
SOB/WK 409 34.5 1 1
PAIN 90 7.6 0 0
MSC 152 12.8 3 0
SURG 37 3.1 10 20
p (a) NS (b) 0.001

 Patients with a clinical diagnosis of ACS, %

 cTnI 0.5-1.9 cTnI [greater than or
Complaints [micro]g/L equal to] 2.0 [micro]g/L

CP 21 81
ARRY 17 100
SOB/WK 2 80
PAIN 8 100
MSC 8 88
SURG 0 100
p (a) 0.01 NS

(a) Differences among the six patient groups with various
complaints were assessed by [chi square] test for independence.

(b) NS, not significant.

Table 2. cTnI, demographic characteristics, and disease frequencies
for patients with CP or anginal equivalent symptoms.

Presented with CP ARRY SOB/WK PAIN

Median cTnI, [micro]g/L 0.1 0.2 0.2 0.0
0.5 [less than or equal to] 16 18 22 14
 cTnI < 2.0 g/L, %
cTnI [greater than 6 6 7 1
 or equal to] 2.0 g/L, %
BMI, kg/[m.sup.2] 29 27 27 27
Total cholesterol, mg/L 1870 1930 1740 1710
Serum creatinine, mg/L 15 13 20 16
Mean blood pressure, mmHg 97 101 99 98
Mean age, years 61 65 67 64
African American, % 44 17 43 53
Male, % 95 100 98 100
Smoking, % 73 67 73 64
Diabetes, % 30 21 37 40
CHF, % 15 13 40 9
Coronary artery disease, % 47 29 45 35
Angioplasty, % 23 13 16 13
Cerebrovascular accident, % 14 17 20 15
Cancer, % 13 29 17 18
COPD, % 17 17 28 18
Outpatients, % 84 50 66 70

Presented with MSC SURG p (a)

Median cTnI, [micro]g/L 0.1 0.0 NS (b)
0.5 [less than or equal to] 17 13 NS
 cTnI < 2.0 g/L, %
cTnI [greater than 5 3 NS
 or equal to] 2.0 g/L, %
BMI, kg/[m.sup.2] 26 24 <0.001
Total cholesterol, mg/L 1810 1550 <0.001
Serum creatinine, mg/L 18 10 0.01
Mean blood pressure, mmHg 97 90 NS
Mean age, years 62 67 <0.001
African American, % 56 24 0.05
Male, % 98 95 NS
Smoking, % 64 71 NS
Diabetes, % 31 19 NS
CHF, % 16 10 <0.001
Coronary artery disease, % 31 33 0.05
Angioplasty, % 11 10 NS
Cerebrovascular accident, % 17 24 NS
Cancer, % 12 52 <0.001
COPD, % 17 33 0.01
Outpatients, % 82 14 <0.001

(a) Comparisons among presentations were conducted using ANOVA
for continuous variables and 2 analysis for categorical values.

(b) NS, not significant.

Table 3. Multivariate predictors and P values for 200-day mortality
among patients with various complaints at the time of
laboratory testing.

 Complaints (a)


 Odds ratio P

BMI 0.93 (0.86-1.01) NS (b)
Creatinine VR
Mean blood pressure VR
Age 1.06 (1.02-1.11) 0.001
Cancer 3.50 (1.44-8.48) 0.01

cTnI < 2 g/L VR
cTnI [greater than 4.70 (1.52-14.56) 0.01
 or equal to] 2 g/L

 Complaints (a)


 Odds ratio P
Creatinine 0.93 (0.89-0.97) 0.001
Mean blood pressure 1.26 (1.12-1.43) 0.001
Age 0.98 (0.96-0.99) 0.001
CVA 1.02 (1.01-1.05) 0.05
Cancer VR
 1.88 (1.02-3.47) 0.05
cTnI < 2 g/L
cTnI [greater than See Table 4
 or equal to] 2 g/L See Table 4

 Complaints (a)

 Other, excluding surgery

 Odds ratio P
Creatinine 0.88 (0.80-0.96) 0.01
Mean blood pressure VR
Age VR
CVA 1.09 (1.05-1.13) 0.001
Cancer VR
cTnI < 2 g/L
cTnI [greater than VR
 or equal to] 2 g/L 1.64 (0.30-9.09) NS

(a) 95% confidence intervals are shown in parentheses.

(b) NS, not significant; VR, variable removed from final step of
equation; CVA, cerebrovascular accident.

Table 4. Odds of death within 200 days for patients
presenting with SOB/WK of any cause or for patients with
any complaint and a previous history of CHF.

 Odds 95% confidence
cTnI, [micro]g/L Presentation n ratio interval

0.0-0.1 SOB/WK 178 1
 CHF 117 1
0.2-0.4 SOB/WK 108 3.07 1.61-5.85
 CHF 76 4.34 1.66-11.30
0.5-1.9 SOB/WK 89 2.81 1.44-5.50
 CHF 62 5.68 2.09-15.39
[greater than or SOB/WK 30 6.58 2.65-16.34
 equal to] 2.0 CHF 19 13.04 3.74-45.48

cTnI, [micro]g/L P


0.2-0.4 <0.001
0.5-1.9 <0.01
[greater than or <0.001
 equal to] 2.0 <0.001
COPYRIGHT 2004 American Association for Clinical Chemistry, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Evidence-based Laboratory Medicine and Test Utilization
Author:Ritter, Detlef; Lee, Paul A.; Taylor, James F.; Hsu, Leo; Cohen, Jerome D.; Chung, Hyung D.; Virgo,
Publication:Clinical Chemistry
Date:Jan 1, 2004
Previous Article:Diagnosis of congenital disorders of glycosylation by capillary zone electrophoresis of serum transferrin.
Next Article:Definitive diagnosis of mitochondrial neurogastrointestinal encephalomyopathy by biochemical assays.

Related Articles
National academy of clinical biochemistry laboratory medicine practice guidelines: use of cardiac troponin and B-type natriuretic peptide or...
Use of the Centaur TnI-Ultra assay for detection of myocardial infarction and adverse events in patients presenting with symptoms suggestive of acute...
Cardiac troponin and creatine kinase MB monitoring during in-hospital myocardial reinfarction.
Point-of-care i-STAT cardiac troponin I for assessment of patients with symptoms suggestive of acute coronary syndrome.
Near-bedside whole-blood cardiac troponin I assay for risk assessment of patients with acute coronary syndromes.
Quantitative bedside assay for cardiac troponin T: a complementary method to centralized laboratory testing.
Improved detection of minor ischemic myocardial injury with measurement of serum cardiac troponin I.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters